Chronic Hypertension in Pregnancy
Definition
Chronic hypertension in pregnancy is defined as:
- A pre-existing diagnosis of hypertension, OR
- SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg on 2 occasions at least 4 hours apart before 20 weeks' gestation
(ACC/AHA Guidelines on High Blood Pressure in Adults, p. 64)
It is distinguished from gestational hypertension and preeclampsia, which arise at or after 20 weeks.
Classification of Hypertensive Disorders of Pregnancy
| Disorder | Onset | Key Features |
|---|
| Chronic hypertension | < 20 weeks or pre-existing | No proteinuria required; persists postpartum |
| Gestational hypertension | ≥ 20 weeks | No proteinuria; resolves postpartum |
| Preeclampsia | ≥ 20 weeks | HTN + proteinuria or end-organ damage |
| Superimposed preeclampsia | ≥ 20 weeks in chronic HTN patient | Worsening HTN + new proteinuria/end-organ damage |
| Eclampsia | Any time | Preeclampsia + seizures |
Risks & Complications
Women with chronic hypertension face elevated maternal and fetal risks (Harrison's, 21st Ed., p. 13634):
Maternal:
- Superimposed preeclampsia (most important complication; risk 15–25%)
- Placental abruption
- Stroke / hypertensive crisis
- Renal deterioration
- Cardiac failure (in severe/long-standing HTN)
Fetal/Neonatal:
- Intrauterine growth restriction (IUGR)
- Preterm birth
- Placental insufficiency
- Perinatal mortality (increased)
Pre-pregnancy & Early Pregnancy Evaluation
A thorough assessment should include (Harrison's, 21st Ed., p. 13634):
- Identify secondary/remediable causes of hypertension
- End-organ assessment — renal function, proteinuria (baseline), cardiac evaluation, fundoscopy
- Transition off teratogenic antihypertensives (especially ACE inhibitors and ARBs) before conception or as soon as pregnancy is confirmed
- Baseline proteinuria — helps differentiate pre-existing renal disease from later-developing preeclampsia
Blood Pressure Targets in Pregnancy
| Parameter | Target |
|---|
| Systolic BP | 130–150 mmHg |
| Diastolic BP | 80–100 mmHg |
| Emergency threshold | SBP ≥ 160 or DBP ≥ 110 → immediate hospitalization |
Targets balance maternal safety (preventing stroke, end-organ damage) with fetal perfusion (avoiding uteroplacental insufficiency from over-aggressive lowering). (Harrison's, p. 13634; Management of Elevated BP Guidelines, p. 60)
Antihypertensive Drug Management
First-Line Agents (Safe in Pregnancy)
| Drug | Class | Notes |
|---|
| Labetalol | α/β-blocker | Most commonly used; IV form for acute management |
| Nifedipine (extended-release) | Dihydropyridine CCB | Oral; preferred for outpatient chronic management |
| Methyldopa | Central α2-agonist | Long safety record; less preferred due to side effects |
(Harrison's, p. 13634; Management of Elevated BP Guidelines, p. 60)
Contraindicated in Pregnancy
| Drug Class | Reason |
|---|
| ACE inhibitors (e.g., enalapril, lisinopril) | Fetotoxic — renal dysgenesis, oligohydramnios, skull hypoplasia |
| Angiotensin Receptor Blockers (ARBs) | Same mechanism as ACEi; equally teratogenic |
| Direct renin inhibitors (e.g., aliskiren) | Insufficient safety data; avoid |
| Mineralocorticoid receptor antagonists (e.g., spironolactone) | Anti-androgenic effects on fetus |
Management Guidelines Summary
(Management of Elevated Blood Pressure and Hypertension Guidelines, p. 60)
Monitoring During Pregnancy
- Frequent antenatal visits — every 2–4 weeks (more frequent if poorly controlled)
- BP monitoring: Home BP monitoring (HBPM) and/or ambulatory BP monitoring (ABPM) to exclude white-coat and masked hypertension (more common in pregnancy)
- Urine protein at each visit — early detection of superimposed preeclampsia
- Fetal surveillance: Serial growth ultrasounds (every 4 weeks from 28 weeks), umbilical artery Doppler, non-stress tests
- Labs: Renal function, LFTs, CBC, uric acid
Delivery Planning
| Scenario | Timing |
|---|
| Well-controlled chronic HTN, no complications | 38–39 weeks |
| Poorly controlled or with superimposed preeclampsia | Earlier delivery; individualized |
| Severe features (SBP ≥160 or DBP ≥110, organ damage) | Expedite delivery after stabilization |
Postpartum Considerations
- BP often rises 3–6 days postpartum — close monitoring required
- Resume or initiate antihypertensives as needed; most are compatible with breastfeeding (labetalol, nifedipine, methyldopa)
- ACE inhibitors (e.g., enalapril, captopril) are acceptable postpartum and in breastfeeding
- Evaluate for secondary causes postpartum if not done previously
- Long-term: chronic hypertension persists — ongoing cardiovascular risk management